Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropinirole Implants in Parkinson's Disease
NCT03250117Phase 2Terminated
- Sponsor
- Titan Pharmaceuticals, Inc.
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ropinirole in Parkinson's disease (PD) (4 cohorts), sponsored by Titan Pharmaceuticals, Inc. Primary endpoints: Area Under the Curve 0-24 Hours of Ropinirole and Total Number of Adverse Events Across Participants. Started Oct 2017; status: terminated.
02
Drugs
ropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03250117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250117.